Demand for hyperactivity drugs in the US drove a 24 per cent rise in third-quarter revenues for Shire.
The specialist pharmaceutical firm said its total revenues rose to $1.09bn between July and September as product sales surged by 28 per cent to $1.02bn. Alongside demand for its hyperactivity treatments, Shire also reported strong sales for its rare disease medicines. Sales of its Vyvanse attention deficit hyperactivity disorder drug were up by 32 per cent to about $200m. Drawing strength from the results, Shire chief executive Angus Russell said the company was on track to meet market expectations for the full year.